Clinical Trials
- Digestive System
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
- Ages12 years - 75 years
- GenderBoth
- Digestive System
test
- Ages40 years and older
- GenderBoth
- Digestive System
Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)
- Ages60 years - 84 years
- GenderBoth
- Colorectal Cancer, Breast Cancer, Gynecological Cancers, Stomach and Esophagus, Lymphoma, Kidney Cancer, Head and Neck Cancers, Liver Cancer, Lung Cancer, Melanoma, Thyroid and Other Endocrine Cancers, Other Cancers, Bladder Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma Cancers, Phase 1 Cancers, Cancer
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer
- Phase 1 Cancers
test
- Phase 1 Cancers
test
- Digestive System
test
- Ages18 years - 75 years
- GenderBoth
- Digestive System
test
- Ages18 years - 75 years
- GenderBoth
- Lung Cancer
test